Reverse Positive Pay Sample Clauses

The Reverse Positive Pay clause is designed to help prevent check fraud by allowing a bank to notify a business of checks presented for payment before they are cleared. In practice, the bank provides the business with a list of checks that have been presented, and the business must review and confirm which checks are legitimate before the bank processes payment. This process gives the business an opportunity to detect and stop unauthorized or fraudulent checks, thereby reducing the risk of financial loss due to check fraud.
POPULAR SAMPLE Copied 1 times
Reverse Positive Pay. If Reverse Positive Pay is selected, on each Business Day, Bank will provide notification and post a list of Presented Checks on ONPointe for Client to make “Return” decisions. Checks will be paid unless Client makes a “Return” decision by the applicable response Cutoff Time.
View SourceView Similar (2)
Reverse Positive Pay. Upon enrollment of Reverse Positive Pay (an optional service), Bank will make available to Company a Reverse Positive Pay Extract. It is Company’s responsibility to review the Reverse Positive Pay Extract and communicate to Bank, in a manner acceptable to Bank, its decision to return any applicable item. If Company fails to communicate the return decision by the Positive Pay Cut-Off time listed in the Positive Pay Configuration/Training Checklist, the checks in the Reverse Positive Pay Extract will be paid. Checks presented at the teller line for deposit will be provided for Company’s review on the following business day. The Reverse Positive Pay service is not available for checks presented at the teller line for cash.
View SourceView Similar (2)
Reverse Positive Pay. Cut-Off 9:30 p.m. 8:30 p.m. • Presentment Transmission For items received by us prior to the Cut-Off on any banking day, the daily transmission will generally be made available at 4:00 a.m. on the next banking day following presentment (items received after the Cut-Off may be made available on the following banking day). For items received by us prior to the Cut-Off on any banking day, the daily transmission will generally be made available at 3:00 a.m. on the next banking day following presentment (items received after the Cut-Off may be made available on the following banking day). • Bouncer Deadline 2:00 p.m. on the same day that we transmitted the daily transmission to which the bouncer sheet relates. 1:00 p.m. on the same day that we transmitted the daily transmission to which the bouncer sheet relates. • Cut-Off Bank Routing/Transit (“RT”) – 10:00 p.m. Bank Routing/Transit (“RT”) – 9:00 p.m. • Presentment Transmission Bank RT-For Drafts received by us prior to the Cut-Off On any banking day, a Draft List may be made available to you, on request, generally by 4:00 a.m. on the Following bnking day. Bank RT-For Drafts received by us prior to the Cut-Off On any banking day, a Draft List may be made available to you, on request, generally by 3:00 a.m. on the Following bnking day. • Bouncer Deadline 10:00 a.m. on the next banking day following the date of the Draft List identifying the relevant Draft. 9:00 a.m. on the next banking day following the date of the Draft List identifying the relevant Draft. • Bouncer Acknowledgment ury Services Agreement ember 2022 1:00 p.m. on the day we receive the Draft Bouncer Sheet, if received prior to the Bouncer Deadline. 12:00 noon on the day we receive the Draft Bouncer Sheet, if received prior to the Bouncer Deadline. Page 43 of 57 Link to Top Exhibit 1 Link to Table of Contents • Cut-Off Controlled Disbursement Routing/ Transit (“RT”) – 12:00 noon (or later based on FRB Presentment Delivery) • Presentment Transmission Controlled Disbursement RT – For drafts received by us prior to the Cut- Off on any banking day, if requested, a Draft List may generally be made available to you by 1:00 p.m. on such day. Drafts received after the Cut-Off will be presented on the Draft List for the next banking day. • Bouncer Deadline 10:00 a.m. on the next banking day following the date of the Draft List identifying the relevant Draft. • Bouncer Acknowledgment 1:00 p.m. on the day we receive the Draft Bouncer Sheet, if received prior...
View SourceView Similar (2)
Reverse Positive Pay. If this option is selected, Bank will provide a list of all Presented Checks on each Business Day for Client to review and decision.
View Source
Reverse Positive Pay. With Reverse Positive Pay, Client must monitor the Service every Business Day and review and decision each Presented Check by the applicable Cutoff Time. All Presented Checks will be paid in accordance with Bank’s standard Check processing procedures unless Client submits a “Return” decision by the Cutoff Time. Client understands that Reverse Positive Pay does not provide fraud prevention benefits with respect to Presented Checks that Client fails to timely review and decision if such Checks are fraudulent, and Client will be deemed to have accepted this risk if Client fails to timely review and decision Presented Checks.
View Source
Reverse Positive Pay a. Wesbanco will provide the Client with an electronic file or online access detailing all checks presented for payment against the Client’s account(s). b. Each morning, WesBanco will present in CashFlow Connect a report of checks that will have been presented for payment and which are ready for Client to make a decision whether to pay or return the Items. .
View Source
Reverse Positive Pay. If Customer chooses this option, Customer will not have the ability to upload a file or manually input issued checks to be matched. All Presented Checks will appear on the Check Exceptions.
View Source
Reverse Positive Pay 
View Source

Related to Reverse Positive Pay

  • Special Parental Allowance for Totally Disabled Employees (a) An employee who: (i) fails to satisfy the eligibility requirement specified in subparagraph 17.05(a)(ii) solely because a concurrent entitlement to benefits under the Disability Insurance (DI) Plan, the Long-term Disability (LTD) Insurance portion of the Public Service Management Insurance Plan (PSMIP) or via the Government Employees Compensation Act prevents the employee from receiving Employment Insurance or Québec Parental Insurance Plan benefits, and (ii) has satisfied all of the other eligibility criteria specified in paragraph 17.05(a), other than those specified in sections (A) and (B) of subparagraph 17.05(a)(iii), shall be paid, in respect of each week of benefits under the parental allowance not received for the reason described in subparagraph (i), the difference between ninety-three per cent (93%) of the employee's rate of pay and the gross amount of his or her weekly disability benefit under the DI Plan, the LTD Plan or via the Government Employees Compensation Act. (b) An employee shall be paid an allowance under this clause and under clause 17.05 for a combined period of no more than the number of weeks during which the employee would have been eligible for parental, paternity or adoption benefits under the Employment Insurance or Québec Parental Insurance Plan, had the employee not been disqualified from Employment Insurance or Québec Parental Insurance Plan benefits for the reasons described in subparagraph (a)(i).

  • Qualifying Termination If the Executive is subject to a Qualifying Termination, then, subject to Sections 4, 9, and 10 below, Executive will be entitled to the following benefits:

  • Special Maternity Allowance for Totally Disabled Employees (a) An employee who: (i) fails to satisfy the eligibility requirement specified in subparagraph 17.02(a)(ii) solely because a concurrent entitlement to benefits under the Disability Insurance (DI) Plan, the Long term Disability (LTD) Insurance portion of the Public Service Management Insurance Plan (PSMIP) or the Government Employees Compensation Act prevents her from receiving Employment Insurance or Québec Parental Insurance Plan maternity benefits, and (ii) has satisfied all of the other eligibility criteria specified in paragraph 17.02(a), other than those specified in sections (A) and (B) of subparagraph 17.02(a)(iii), shall be paid, in respect of each week of maternity allowance not received for the reason described in subparagraph (i), the difference between ninety-three per cent (93%) of her weekly rate of pay and the gross amount of her weekly disability benefit under the DI Plan, the LTD Plan or via the Government Employees Compensation Act. (b) An employee shall be paid an allowance under this clause and under clause 17.02 for a combined period of no more than the number of weeks during which she would have been eligible for maternity benefits under the Employment Insurance or Québec Parental Insurance Plan had she not been disqualified from Employment Insurance or Québec Parental Insurance maternity benefits for the reasons described in subparagraph (a)(i).

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Sick Leave Separation Cash Out At the time of retirement from state service or at death, an eligible employee or the employee’s estate will receive cash for their compensable sick leave balance on a one (1) hour for four (4) hours basis. For the purposes of this Section, retirement will not include “vested out of service” employees who leave funds on deposit with the retirement system.